CytoDyn (CYDY) Receivables (2011 - 2025)

CytoDyn (CYDY) posted Receivables of $2.0 million for Q2 2025, little changed on a QoQ basis from $2.0 million in Q1 2025.

CytoDyn (CYDY) Receivables (2011 - 2025) Analysis & Trends

CytoDyn's Receivables history runs 4 years deep, the most recent figure standing at $2.0 million for Q2 2025.

Quarterly Receivables changed N/A year-over-year to $2.0 million in Q2 2025, while the trailing twelve-month figure through May 2025 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.0 million, changed N/A from the prior year.
Receivables was $2.0 million for Q2 2025 at CytoDyn, roughly flat from $2.0 million in the prior quarter.
Across five years, Receivables topped out at $2.0 million in Q3 2024 and bottomed at $41000.0 in Q3 2021.
A 3-year average of $1.4 million and a median of $2.0 million in 2024 frame the typical range for Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Download Data